Top Markets
Coin of the day
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
Hisse Senetlerindeki Sıralama #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Hisse Fiyatı
$5.47
Son senkronizasyon: 2026-08-14
Piyasa Değeri
$7.99M
Değişim (1 gün)
6.21%
Değişim (1 yıl)
7.47%
Ülke
US
Ticaret CNS Pharmaceuticals, Inc. (CNSP)

Kategori

CNS Pharmaceuticals, Inc. (CNSP) için kazanç
2026 itibarıyla kazanç TTM: 0
CNS Pharmaceuticals, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
CNS Pharmaceuticals, Inc. için kazanç geçmişi 2026 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE